Prostate Cancer

During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.

A 75-year-old man presented with intermittent right hip pain. The case was discussed between of physicians and moderated by Nauman Moazzam, MD.

Alicia K. Morgans, MD, PhD, an associate professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine, gives an overview of androgen receptor therapy in men with non-metastatic castration-resistant prostate cancer.

Dr. Morgans discusses unmet needs and importance of including multidisciplinary teams when treating patients with mCRPC.

A review of the data from phase 3 randomized Phase 3 Study of 177Lu-PSMA-617 or best supportive/standard of care, VISION, in the treatment of patients with progressive PSMA-positive mCRPC and Dr. Morgans’ experience with 177Lu-PSMA-617.

Dr. Morgans talks about available second-line treatment options for patients with mCRPC and considerations when choosing second and subsequent-line treatment options.

An overview of how patients with mCRPC are monitored and followed-up in practice and the triggers to reevaluate the treatment patient is receiving.

Dr. Morgans discusses first-line therapy options for mCRPC and her approach to deciding between different treatment options.

Alicia Morgans, MD, MPH presents the case of a 70-year-old man with progressive PSMA-positive mCRPC.

A patient with metastatic castration-resistant prostate cancer received external beam radiation therapy and androgen deprivation therapy became asymptomatic, then presented with hip pain and urinary frequency 6 months later.

During separate virtual live events, Matthew A. Gubens, MD, MS, and Rodolfo Bordoni, MD, discussed the CASPIAN trial of durvalumab plus platinum therapy and etoposide and whether the participants have used this regimen in patients with small cell lung cancer.

David I. Quinn, MD, MBBS, PhD and other oncologists, discussed disease management and the option of using an osteoclast-targeting agent for a 75-year-old man with metastatic castration-resistant prostate cancer.

One year following treatment with androgen deprivation therapy, a 57-year-old patients with nonmetastatic castration-resistant prostate cancer presented again with a PSA doubling time of 8.6 months and was still nonmetastatic.

Positive findings from the phase 3 VISION have led the FDA to grant priority review to 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology Case-Based Roundtable event, Petros Grivas, MD, PhD, discussed the case of a 75-year-old patient with castration-resistant prostate cancer.

In this second video of the series, Phillip J. Koo, MD, of the Banner MD Anderson Cancer Center explains the role of nuclear imaging (PET) and PSMA in the diagnosis and treatment of prostate cancer.

A phenomenon known as the “obesity paradox,” has been reported in prostate cancer as well as other genitourinary malignancies.

The phase 3 PROpel clinical trial has achieved its primary end point of improvement in radiographic progression-free survival in men with metastatic castration resistant prostate cancer using the novel combination of olaparib and abiraterone.

The FDA authorized the marketing of Paige Prostate, the first ratification-intelligence-based software designed to identify areas with high likelihood of cancer on images from a prostate biopsy.

In an interview with Targeted Oncology, Ashley E. Ross, MD, PhD, discusses new prostate cancer screening and staging options as well as therapies for both earlier and later-stage disease.

Neeraj Agarwal, MD, discusses how the prostate-specific antigen responses correlate with survival outcomes in 2 phase 3 trials of apalutamide in patients with advanced prostate cancer.

A study has confirmed that androgen receptor inhibition did not complicate robotic prostatectomy surgical outcomes in patients with prostate cancer.

A safety analysis from the phase 3 ARAMIS trial showed that tolerability with darolutamide was comparable with that of placebo in patients with nonmetastatic castration-resistant prostate cancer.

In patients with high-risk nonmetastatic prostate cancer treatment involving abiraterone acetate and prednisolone with or without enzalutamide added to androgen deprivation therapy for 2 years led to meaningfully enhanced survival outcomes.

In patients with metastatic castration resistant prostate cancer, sabizabulin was well tolerated and associated with significant and durable objective tumor responses